Introduction
Arabinosylcytosine (ara-C) is the main component in treatment protocols for acute myelogenous leukemia [19] , whereas fludarabine is the most active single agent against low-grade lymphocytic malignancies, especially chronic lymphocytic leukemia (CLL) [20, 21] . The metabolism and mechanisms of action of both compounds are closely related, The first step, which is rate-limiting in their phosphorylation to the respective active triphosphates, is mediated by deoxycytidine kinase (dCyd kinase) [2, 10, 24, 26] . The acfvity of this enzyme is regulated by the cellular nucleotide pools [9, 11, 25] . In addition, ara-C 5'-triphosphate (ara-CTP) may exert feedback inhibition on dCyd kinase [7, 14, 28] . In contrast, the 5'-triphosphate of fludarabine (F-ara-ATP) stimulates dCyd kinase activity both indirectly by lowering the deoxynucleotide pool through the inhibition of ribonucleotide reductase [2, 14, 32] and by an apparent direct action on the enzyme [14] . A positive correlation between the cellular pharmacokinetics of ara-CTP in circulating leukemia blasts and the clinical response to treatment has been established [12, 13, 18, 30] . Strategies were therefore sought to increase the accumulation of ara-CTP through metabolic modulation by fludarabine.
When incubated in vitro with arabinosyl-2-fluoroadenine (F-ara-A), K562 ceils or freshly isotated leukemic lymphocytes accumulated ara-CTP at a higher rate to greater concentrations than did cells exposed to ara-C alone [14, 15] . On the basis of these studies, we designed three different treatment protocols for patients with CLL or acute leukemias, in which fhidarabine was infused prior to ara-C. Ara-CTP accumulation was potenti- ated in circulating leukemia cells from patients who received the combination therapy [16, 17] . Studying the modulation of ara-C metabolism by fludarabine in clinical trials provided the opportunity to investigate two pharmacokinetic sequelae that have a potential impact on drag scheduling. First, on the basis of the kinetic characteristics of dCyd kinase, we hypothesized that the relatively high plasma concentrations of ara-C (>10 gM) would compete effectively for phosphorylation against the lower levels of F-ara-A (0.3-0.7 ~M), the nucleoside product of fludarabine dephosphorylation. Second, on the basis of studies in K562 cells, we expected that intracellular ara-CTP would inhibit F-ara-ATP accumulation, presumably through feedback inhibition of dCyd kinase. Thus, the pharmacokinetics of plasma F-ara-A and, consequently, of intracellular F-ara-ATP may be perturbed.
Patients and methods
Treatment. After informed consent had been obtained, patients were entered in one of the four treatment plans. Patients with refractory CLL received 30 mg/m 2 fludarabine (F-ara-AMP, the clinical formulation of F-ara-A) in a 30-rain i.v. infusion either as a single agent (n = 6) or in combination with ara-C (0.5 g/m 2 given over 2 h) infused at 20 h before and 4 h after the administration of fludarabine (n = 7). Adults with acute leukemia in relapse were treated with the same drug combination, except that the ara-C dose was either 1 g/m 2 infused over 2 h (n = 6) or 3 g/m 2 infused over 6 h (n = 6).
Materials.
As chromatographic standards F-ara-A was supplied by Berlex Laboratories, Inc. (Alameda, Calif.) and [8-3H]-F-ara-A was obtained from Moravek Biochemicals (Brea, Calif.). F-ara-ATP was synthesized by Dr. A. Sen in this laboratory [29] . Ara-CTP and other ribonucleotides used as standards were purchased from Sigma (St. Louis, Mo). Erythro-9-(2-hydroxy-3-nonyl)adenine was a gift from Dr. T. A. Krenitsky (Burroughs Wellcome, Research, Triangle Park, N.C.) and tetrahydrouridine was obtained from Dr. V. Narayanan of the Drug Synthesis and Chemistry Branch of the National Cancer Institute (Bethesda, Md.). The SEP-PAK ClS cartridges were supplied by Waters Associates (Milford, Mass.). All other chemicals used were of the highest purity available.
Preparation ofplasma andperipheral mononuclear cells. Blood samples (5-10 nil) obtained through a peripheral catheter were immediately transferred into a heparinized glass tube containing 1 UM erythro-9-(2-hydroxy-3-nonyl)adenine (to inhibit adenosine deaminase) and 500 gM tetrahydrouridine (to inhibit cytidine deaminase), which was placed in an ice bath. After centrifugation at 500 g for 20 rain at 4 ~ C, the plasma was removed and stored at -20 ~ C. The cell pellet was resuspended in 40 ml phosphate-buffered saline (NaC1, 8.1 g/l; NazHPO4, 1.14 g/l; KC1, 0.22 g/l; KH2PO4, 0.27 g/l) and layered over a 10-ml Ficoll-Hypaque mixture (sp. gr., 1.077 g/ml). After centrifugation at 400 g for 20 min at 4 ~ C, the buoyant mononuclear cells were removed and diluted to 10 rnl with phosphate-buffered saline. Duplicate analyses of the mean cell number and cell volume were done with a model ZM Coulter counter equipped with a 100-channel particle-size analyzer (model C1000). Cellular nucleotides were extracted with 0.4 M HCIO4, neutralized with KOH, and stored at-20~ [14] .
Quantitation of nucleosides in plasma and cellular nucleotides. F-ara-A plasma levels were determined by high-pressure liquid chromatography with fluorescence detection using a method described in detail elsewhere [22] . In brief, the nucleoside was isolated from plasma by solid-phase extraction (elution from SEP-PAK C18 cartridges with alkaline methanol). After derivatization with chloroacetaldehyde to the fluorescent arabinosyl-etheno-isoguanine, the product was separated from other fluorescent compounds by reverse-phase high-pressure liquid chroma- ). F-ara-A concentrations in patient samples were calculated by comparing peak areas of the fluorescent derivative to those of standard samples spiked with F-ara-A that had been processed simultaneously. Ara-C plasma levels were determined by reverse-phase high-pressure liquid chromatography according to the method described by Breithanpt [1] . The steady-state plasma ara-C concentration is expressed as the mean of the values obtained in the samples taken at 1 and 2 h (2-h infusion) or, generally, as 1-to 6-h (6-h infusion) values found for ara-C in plasma.
The concentrations of intracellular ara-CTP and F-ara-ATP were determined by ion-exchange high-pressure liquid chromatography (Partisil-10 SAX column) with UV detection [14] .
Pharmacokinetic data analysis. Analyses of pharmacokinetic data were performed using the computer program ESTRIP [3] . The F-ara-A plasma concentration-time data were stripped according to the i. v./postabsorption type, except for the samples that showed a transient increase in F-ara-A plasma levels. Then, the data sets were divided into two phases that were processed separately: the first phase, from the end of the infusion to the last time point prior to the increase in F-ara-A concentration, was stripped using the i. v./postabsorption type; the second phase, starting with the lowest concentration prior to the increase, was processed according to the absorption type. Both partial area under the curve (AUC) values were added to give the overall AUC. The increases in AUC caused by ara-C perturbation of the F-ara-A elimination kinetics (AUCp) were determined gravimetrically by overlaying the actual curve with a hypothetical, unperturbed elimination curve generated from the early data points (before perturbation) and the late data points (>10 h). Elimination half-lives of perturbed F-ara-A concentration-time data sets were obtained by processing only the data acquired after the occurence of the peak or platean concentration according to the i.v./postabsorption type. For pharmacokinetic analysis of intracellular F-ara-ATP, the concentration-time data were stripped according to the absorption type. The statistical significance of differences between the data sets was assessed by Student' s two-tailed t-test.
Purification of dCyd kinase and determination of its activity, dCyd
kinase was purified from a routine L-cell expression vector containing the cDNA sequence for the enzyme as described in detail elsewhere [6] . For determination of the Ki value (inhibition constant) for ara-C on dCyd kinase phosphorylation of F-ara-A, 15 gl of the desalted enzyme was added to 15 gl ice-cold reaction mix to achieve a final concentration of 50 mM imidazole/HC1 buffer (pH 7.4), 25 mM dithiothreitol, 2 mM ATP, 2.5 rnM MgC12, 100-600 gM [3H]-F-ara-A, 0-40 gM ara-C, 1 nag bovine serum albumiu/ml and 10% glycerol. After incubation for 20 rain at 37 ~ C, the reaction was terminated by heating the sample for 1 rain at 85 ~ C. The radiochemical quantitation of phosphorylated F-ara-A was performed as previously described [9] . Lines describing the double reciprocal plots were calculated according to a weighted fit program described by Wilkinson [35] . The resulting slope values were plotted against the ara-C concentrations, and the apparent Ki va~me was estimated from linear regression analysis.
Results

Influence of ara-C infusion on the plasma pharmacokinetics of F-ara-A
The plasma pharmacokinetics of F-ara-A was compared between patients receiving fludarabine as monotherapy and those additionally treated with an ara-C infusion. Figure 1 shows the data of four patients, each representative of the respective therapy group. The triphasic plasma-elimination kinetics of F-ara-A in patients receiving fludarabine monotherapy (Fig. 1 A) was perturbed by ara-C infusions in all three combination therapy protocols ( Fig. 1 B-D) . The F-ara-A plasma levels either increased ( Fig. 1 B, C) or plateaued ( Fig. 1 D) during the ara-C infusions. The increase in AUC caused by this transient rise in F-ara-A plasma concentration seemed to be dependent on the ara-C dose, with saturation occurring at 1 g/m2 ara-C ( Fig. 2A ; P = 0.068 for the difference between mean AUCp values at 0.5 g/m 2 for 2 h vs 1 g/m 2 for 2 h). At the same time, the terminal half-lives of F-ara-A decreased with increasing ara-C dose ( Fig. 2B ; P = 0.184 at 0.5 g/m2, P = 0.006 at 1 g/m 2, and P = 0.001 at 3 g/m 2 as compared with that obtained during fludarabine monotherapy). Although the total AUCs for F-ara-A over 24 h were increased after the various ara-C infusions (0.5 g/m2, 9.2• h; 1 g/m 2, 13.1• h; 3 g/m2, 12.4_+ 5.2 gM h) relative to that observed in the absence of ara-C (7.4 • 3.6 gM h), these changes were not statistically significant. These data suggest that ara-C caused a dose-related redistribution of F-ara-A.
Effect of intracellular ara-CTP on the accumulation of F-ara-ATP
The intracellular pharmacokinetics of F-ara-ATP was studied in patients with CLL receiving fludarabine alone or in combination with ara-C to determine the influence of plasma ara-C and cellular ara-CTP on the accumulation of F-ara-ATP. A comparison of the pharmacokinetic data on F-ara-ATP in circulating leukemic lymphocytes revealed significant changes in patients receiving the combination therapy as compared with those receiving fludarabine alone (Fig. 3A vs Fig. 3B ). The peak concentration of (Table 1) . The time to reach maximal F-ara-ATP concentrations was not changed (3 + 1 h after the start of the infusion in both groups; data not shown). These data agree with previous in vitro studies, which indicate that preloading of cells with ara-CTP inhibits the rate of accumulation of F-ara-ATP [14] . Although the ara-CTP concentrations in CLL lymphocytes ranged between 8 and 63 gM prior to the fludarabine infusion (Table l) , no relationship was observed in these seven patients between the ara-CTP concentration and the subsequent peak F-ara-ATP accumulation as compared in the same individuals. Additionally, these studies indicated that F-ara-ATP elimination tended to be more rapid in leukemic lymphocytes after ara-C infusion (P = 0.109; Table 1 ). As a consequence of lower Cmax values and faster elimination of the F-ara-ATP, the mean total AUC for F-ara-ATP over 24 h was 58% lower (P = 0.050; Table 1 ) in CLL cells exposed to both ara-C and fludarabine as compared with fludarabine alone. The study design for acute leukemias precluded a direct comparison of F-ara-ATP pharmacokinetics in blasts following treatment with fludarabine alone or in combination with ara-C. However, considerable changes in the pharmacokinetics of F-ara-ATP were observed with increasing ara-C doses (Figs. 3 C, D) . At 3 g/m2 ara-C infused over 6 h, the mean peak level of F-ara-ATP was 44% (P = 0.052) of that measured in blasts from patients who had received 1 g/m 2 over 2 h ( Table 1) . The time to reach maximal F-ara-ATP levels was similar in both cases (data not shown). The mean ara-CTP concentrations remaining after the first ara-C infusion of either 1 g/m 2 over 2 h or Table 1 . Pharmacokinetics of F-ara-ATP in leukemia cells after ara-C infusion
Disease
Ara-C dose a n F-ara-ATP (mg/m z) Cmax Table 1 ). F-ara-ATP elimination after the lower ara-C dose was biphasic, with a mean tl/2o~ value of 3.8+-1.9 h and a mean tl/2~ value of 29.4+__ 16.4 h being obtained (Fig. 3C ). Treatment with 3 g/m 2 ara-C resulted in a comparatively short monophasic elimination (mean tl/2, 3.3 +-1.1 h), and F-ara-ATP could no longer be detected at about 12 h after the fludarabine infusion (Fig. 3 D) . These findings indicate that infusion of ara-C altered the elimination kinetics of F-ara-ATP in circulating blasts. As a consequence, the mean AUC for F-ara-ATP in blasts of patients who received 3 g/m2 ara-C over 6 h was 25% (P = 0.007) of that determined for patients treated with 1 g/m 2 over 2 h.
Inhibition of F-ara-A phosphorylation by ara-C using purified dCyd kinase
During the ara-C infusions, steady-state plasma concentrations of ara-C were substantially higher (13+14 gM, 23+--8 gM, and 27+-9 gM; Table 1 ) at ara-C doses of 0.5, 1.0, and 3.0 g/m2, respectively, than those of F-ara-A, which were less than 1 gM at each dose. Because ara-C is a better substrate for phosphorylation by dCyd kinase, phosphorylation of F-ara-A in plasma would be inhibited in the presence of ara-C. This may in part explain the observed perturbations in plasma F-ara-A and cellular F-ara-ATP pharmacokinetics during ara-C infusions. For exploration of this hypothesis, dCyd kinase purified from a murine L-cell expression system containing the cDNA sequence for human T-lymphoblast dCyd kinase was used to determine the inhibitory effect of ara-C on F-ara-A phosphorylation using ATP as the phosphate donor. A Lineweaver-Burk plot of the data revealed an apparent Km value (Michaelis constant) of 1600 gM for F-ara-A. Ara-C was a competitive inhibitor of F-ara-A phosphorylation, with a Ki value of 11.9 gM being obtained (Fig. 4) . By comparison, the Km of dCyd kinase for ara-C in the same system was 14.8 gM.
Discussion
The interference of ara-C with F-ara-A metabolism in vivo was directly visualized by measuring F-ara-A plasma pharmacokinetics during ara-C infusion. A transient increase or a plateau of the F-ara-A plasma levels was observed at the onset of the ara-C infusion (Fig. 1 B-D) , Fig. 2A ). Subsequently, the terminal half-life of F-ara-A was reduced in proportion to the plasma concentration of ara-C (Fig. 2B) . This disturbance of the usual triphasic elimination kinetics of F-ara-A (Fig. 1 A) suggests a redistribution of F-ara-A from the tissues into the plasma.
The terminal half-life of a drug in plasma reflects an equilibrium between the retention of the compound in the tissue and its excretion. This was previously shown to be independent of fludarabine concentration in a dose range of between 80 and 260 mg/m 2 [27] . Under the conditions of therapy, the elimination kinetics of the drug in tissue, measured as the tl/2 of F-ara-ATP in circulating leukemia cells, decreased considerably when ara-C was added to the regimen (Fig. 3 , Table 1 ). The faster elimination of F-ara-A from plasma after treatment with ara-C (Fig. 2 B) therefore reflects a shorter retention of the drug in the tissue. In an earlier investigation using higher fludarabine doses (50-100 mg/m2), pharmacokinetic studies in circulating blasts of eight patients with acute leukemia showed monophasic elimination of F-ara-ATP, with half-lives ranging between 5.2 and over 24 h (mean, 15.1 _+8.0 h; median, 13.5 h [8] ). This suggests that acute leukemia blasts eliminate F-ara-ATP more rapidly than do CLL lymphocytes (Table 1) . Additionally, ara-C infusion perturbed the elimination kinetics of F-ara-ATP, an action that was dependent on the duration of the ara-C infusion. In K562 cells, the elimination kinetics of F-ara-ATP were not changed by prior incubation with ara-C [14] . The experimental conditions, however, differed from the in vivo situation in that the dose of F-ara-A was 30-fold that of ara-C and the cells were washed free of ara-C prior to the addition of F-ara-A.
As predicted from the preclinical data [14, 15] , CLL cells accumulated less F-ara-ATP when the patients had received ara-C at 20 h prior to fludarabine administration (Fig. 3 A, B) . In patients with acute leukemias, two higher ara-C dose levels (1 g/m2 over 2 h and 3 g/m2 over 6 h) were combined with the standard fludarabine dose (30 mg/m 2 over 30 rain). Because fludarabine as a single agent had shown no clinical efficacy in acute leukemias at this dose [33] and was used to modulate ara-C metabolism in our treatment protocols, the protocol design precluded the study of peak F-ara-ATP concentrations in cells that had not previously been exposed to ara-C. However, the median Cmax of accumulated F-ara-ATP in patients who received the higher ara-C dose was considerably lower (60%) than that in patients treated with the lower ara-C dose (Table 1) . A likely explanation for this effect would be a feedback inhibition of dCyd kinase by ara-CTP [7, 14, 28] . In cell-free extracts of K562 cells, the activity of dCyd kinase was previously inhibited by the addition of 100 gM ara-CTP [14] . Thus, it is possible that the ara-CTP concentrations at the time of fludarabine infusion [range, 8-63 gM (n = 7); Table 1 ] were sufficient to exert feedback inhibition of dCyd kinase in the clinical setting [17] .
It seems rather unlikely that the peak concentration of F-ara-ATP was influenced by the second ara-C dose given at 4 h after the start of the fludarabine infusion, as the time to reach peak F-ara-ATP concentrations was the same (3 __+ 1 h) in patients treated in the presence versus the absence of additional ara-C.
The following mechanisms should be considered as explanations for the ara-C-induced perturbations in plasma F-ara-A and, consequently, the pharmacokinetics of F-ara-ATP in leukemia cells. First, consider renal excretion, which is the major route of F-ara-A elimination [23, 27] . Although deamination is responsible for ara-C clearance, the deamination product arabinosyluracil, a substrate for renal excretion, had reached plasma levels of between 50 and 250 gM by the end of the ara-C infusions [17] . Had the renal excretion mechanism been saturated by arabinosyluracil, a plateau followed by a prolonged terminal halflife would have been expected rather than the observed increase in F-ara-A plasma levels followed by their rapid elimination (Fig. 1, Table 1 ). Furthermore, prolonged elevation of F-ara-A plasma levels should have translated into higher rather than lower intracellular concentrations of F-ara-ATP. Therefore, it is unlikely that a competition between the two drugs for renal excretion sites was responsible for the altered F-ara-A elimination kinetics.
Second, the possibility of F-ara-A release from leukemia cells as a consequence of rapid cell kill caused by ara-C is unlikely because the increase in F-ara-A plasma concentrations was measurable at 30 min after the onset of the ara-C infusion. An increase in plasma levels of 2-chlorodeoxyadenosine was previously observed upon lysis of CLL cells, but it occurred several days after drug infusions [4] . In contrast, no significant decrease in the number of leukemia cells was observed at the time at which plasma F-ara-A levels increased.
Competition of the two nucleosides for transport into cells represents a third possibility of explaining the increase in plasma F-ara-A during ara-C infusion. It is likely that both F-ara-A and ara-C are substrates for the same high-capacity facilitated diffusion mechanism [31, 34] . At the time of ara-C infusion, plasma levels of F-ara-A ranged between 0.3 and 0.7 gM (Fig. 1) . In contrast, ara-C concentrations ranged from 16 to 61 gM, levels that might be expected to result in effective competition with F-ara-A for entry into cells.
Finally, because both ara-C and F-ara-A are phosphorylated by dCyd kinase, a competition for this enzyme is likely. The greater affinity of dCyd kinase for ara-C (Kin = 15-41 gM [5, 9, 11, 26] ; present study) as compared with F-ara-A (Krn = 290-1600 gM [2, 16] ; present study) and the differences in plasma concentrations (ara-C levels were 20-50 times greater than those of F-ara-A) support this interpretation. Furthermore, ara-C was found to competitively inhibit F-ara-A phosphorylation in an in vitro experiment using purified dCyd kinase (Fig. 4) . Ara-C concentrations in the range of the Ki value determined in this experiment (11.9 ~tM) were reached or exceeded in the plasma of patients treated with either 0.5 or 1 g/m 2 over 2 h (13 __ 4 gM and 23 + 8 gtM, respectively) or 3 g/m 2 over 6 h (27 __ 9 gM; Table 1 ). In addition, the activity of dCyd kinase may be inhibited by ara-CTP [7, 14, 28] . The ara-CTP concentrations present at the time of fludarabine infusion (Table 1) lay within the range reported to affect the activity of dCyd kinase.
In conclusion, the inhibitory effect of ara-C on the accumulation of F-ara-ATP found in preclinical experiments using leukemia cells was confirmed in the clinical setting by the present study. On the basis of the considerations discussed above, in a protocol using F-ara-A as a biochemical modulator of ara-C, the ara-C should be given as a relatively short-term (e. g., 2-4 h) infusion following fludarabine. This design would help to minimize metabolic interference with the subsequent fludarabine dose.
